A randomized clinical trial will test whether adding liraglutide and metformin to standard hormonal treatment improves remission rates in obese young women with early endometrial cancer who want to preserve fertility.
264 patients plannedRandomized clinical trial testing liraglutide + metformin + LNG-IUD for fertility-preserving endometrial cancer treatment
What the researchers found
This is a clinical trial protocol (not yet completed). The study will randomize 264 obese women (BMI >30, aged 18-45) with endometrial hyperplasia or early-stage endometrial cancer into three groups:
1. LNG-IUD alone (standard care)
2. LNG-IUD + metformin
3. LNG-IUD + metformin + liraglutide
The hypothesis is that the triple combination will achieve higher complete pathological remission rates than LNG-IUD alone, through both direct metabolic effects and weight loss that reduces estrogen-driven cancer growth. The 12-month trial will also track glucose, insulin levels, weight changes, and histological outcomes.
Why it matters
Endometrial cancer rates are rising as obesity increases globally. For young women who want children, current fertility-preserving options have limited success. Adding metabolic interventions like liraglutide could significantly improve remission rates by addressing the obesity-driven metabolic dysfunction that fuels this cancer.
How the study worked
Randomized clinical trial with three parallel arms. 264 women with BMI >30 and endometrial hyperplasia or early-stage endometrial cancer desiring uterine preservation will be enrolled. Primary outcome is complete pathological remission. Secondary outcomes include histological changes, metabolic markers, and weight changes over 12 months.
What this study cannot tell us
This is a protocol publication — no results are available yet. The trial has not been completed or reported. Whether liraglutide's benefits are primarily from weight loss or direct anti-cancer effects won't be fully separable. The BMI >30 enrollment criterion limits generalizability to non-obese patients with endometrial cancer.
How to read the evidence
This is a clinical trial protocol — the study design is rigorous (randomized, three-arm) but no results have been reported yet. The evidence level is currently limited to the rationale supporting the trial design.
When this study was published
Protocol published in 2024 in Life. The trial is ongoing or recently initiated; results are expected after the 12-month follow-up period is completed for all participants.
The bigger picture
This trial represents the convergence of oncology, reproductive medicine, and metabolic therapy. If GLP-1 receptor agonists can improve endometrial cancer remission rates through metabolic optimization, it would open a new treatment paradigm — using peptide-based metabolic drugs as adjuncts to cancer therapy rather than just as diabetes or obesity medications.
Questions still open
- Will liraglutide's potential anti-cancer effects be independent of its weight loss benefits?
- Could semaglutide or tirzepatide provide even greater benefit given their more potent weight loss effects?
- If the triple combination improves remission rates, could it become standard of care for fertility-preserving endometrial cancer treatment?
Common questions
Why might liraglutide help treat endometrial cancer?
What is fertility-preserving treatment for endometrial cancer?
Read the original research
Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial.
Life (Basel, Switzerland), 14(7)
Citation
Leipold, Gergő; Tóth, Richárd; Hársfalvi, Péter; Lőczi, Lotti; Török, Marianna; Keszthelyi, Attila; Ács, Nándor; Lintner, Balázs; Várbíró, Szabolcs; Keszthelyi, Márton. (2024). Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial.. Life (Basel, Switzerland), 14(7). https://doi.org/10.3390/life14070835